Lunesta Has "Encouraging" Debut, Sepracor Says
This article was originally published in The Pink Sheet Daily
Executive Summary
For the week ending April 15, the insomnia agent brought in 21,381 new scripts, resulting in a 5.1% market share, Sepracor said. "It looks like…the principal new Rxs are coming from [Sanofi-Aventis'] Ambien," the company said. Sepracor is planning to pursue labeling adaptations to increase Lunesta's market potential.
You may also be interested in...
Ambien CR Gets FDA Approval; Launch Expected In Mid-September
Sanofi-Aventis' follow-on sleep agent is indicated for insomnia characterized by difficulties in sleep onset or maintenance.
Ambien CR Gets FDA Approval; Launch Expected In Mid-September
Sanofi-Aventis' follow-on sleep agent is indicated for insomnia characterized by difficulties in sleep onset or maintenance.
Sepracor Lunesta Cancer Risk At Center Of FDA Approvability Debate
Reviewing division's "not approvable" recommendation is overruled by Office Director Temple, FDA review documents show.